ReviewStem cells international2019
Therapeutic Potential of Mesenchymal Stem Cells and Their Secretome in the Treatment of Glaucoma.
Review in Stem cells international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 93 citations in OpenAlex.
- Retinal function after intravitreal injection of autologous bone marrow-derived mesenchymal stromal cells in advanced glaucoma.Documenta ophthalmologica. Advances in ophthalmology · 2021Trial
- Sustained functional recovery one year after TFCC debridement with adjuvant umbilical cord-mesenchymal stem cells and secretome therapy: a case report.International journal of surgery case reports · 2026Article
- Pretreated mesenchymal stromal cells and their secretome for kidney disease: mechanisms and applications.Stem cell research & therapy · 2026Review
- Chitosan-rapamycin carbon dots rejuvenate autologous Sca-1⁺ stem cells paracrine function for neuroprotection in normal tension glaucoma.Stem cell research & therapy · 2026Article
- Extracellular Vesicles and Glaucoma: Opportunities and Challenges.Current eye research · 2025Review
- Advances in Stem Cell Therapies for Ocular Diseases: Progress in Clinical Trials and Future Perspectives.Stem cell reviews and reports · 2025Review
- Age-Related Macular Degeneration: Therapeutic Strategies Based on Stem Cells.Stem cell reviews and reports · 2025Review
- Mesenchymal Stem Cell-Derived Exosomes for Ocular Diseases: Therapeutic Mechanisms and Clinical Perspectives.International journal of nanomedicine · 2025Review
- Research on neurotrophic factor for glaucoma: a worldwide bibliometric analysis.International journal of ophthalmology · 2025Article
- Transcriptomic analysis of BM-MSCs identified EGR1 as a transcription factor to fully exploit their therapeutic potential.Biochimica et biophysica acta. Molecular cell research · 2024Article
- Advances in Neuroprotection in Glaucoma: Pharmacological Strategies and Emerging Technologies.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Glaucoma: Current and New Therapeutic Approaches.Biomedicines · 2024Review
- Exosomes: current knowledge and future perspectives.Tissue barriers · 2024Review
- Early detection of optic nerve head changes using optical coherence tomography after using mesenchymal stromal cells as intravitreal therapy in rabbit models of ocular hypertension.Veterinary world · 2024Article
- Regulated Cell Death of Retinal Ganglion Cells in Glaucoma: Molecular Insights and Therapeutic Potentials.Cellular and molecular neurobiology · 2023Review
- Application of a Magnetic Platform in α6 Integrin-Positive iPSC-TM Purification.Bioengineering (Basel, Switzerland) · 2023Article
- Effect of the Enrichment in c-Kit Stem Cell Potential of Foetal Human Amniotic Fluid Cells: Characterization from Single Cell Analysis to the Secretome Content.Biomedicines · 2023Article
- TNF-Stem cells international · 2023Article
- Neuroprotection in Glaucoma: Basic Aspects and Clinical Relevance.Journal of personalized medicine · 2022Review
- Newer advances in medical management of glaucoma.Indian journal of ophthalmology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glaucoma represents a group of progressive optic neuropathies characterized by gradual loss of retinal ganglion cells (RGCs), the neurons that conduct visual information from the retina to the brain. Elevated intraocular pressure (IOP) is considered the main reason for enhanced apoptosis of RGCs in glaucoma. Currently used therapeutic agents are not able to repopulate and/or regenerate injured RGCs and, therefore, are ineffective in most patients with advanced glaucoma. Accordingly, several new therapeutic approaches, including stem cell-based therapy, have been explored for the glaucoma treatment. In this review article, we emphasized current knowledge regarding molecular and cellular mechanisms responsible for beneficial effects of mesenchymal stem cells (MSCs) and their secretome in the treatment of glaucoma. MSCs produce neurotrophins and in an exosome-dependent manner supply injured RGCs with growth factors enhancing their survival and regeneration. Additionally, MSCs are able to generate functional RGC-like cells and induce proliferation of retinal stem cells. By supporting integrity of trabecular meshwork, transplanted MSCs alleviate IOP resulting in reduced loss of RGCs. Moreover, MSCs are able to attenuate T cell-driven retinal inflammation providing protection to the injured retinal tissue. In summing up, due to their capacity for neuroprotection and immunomodulation, MSCs and their secretome could be explored in upcoming clinical studies as new therapeutic agents for glaucoma treatment.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.